Ascendis Pharma A/S
NASDAQ:ASNDBiotechnology
-$0.05 today
- Market cap
- $17.73B
- Beta
- 0.39
- P/E (TTM)
- 24.5
- EPS (TTM)
- $8.21
Volume 0.57M
Average 0.64M
ASND Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ascendis Pharma A/SNASDAQ: ASND
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables declines year over year
Q3 FY2026 accounts receivables of €17.55M (cash outflow) fell 29.5% year over year, behind the -11.3% change in trailing-twelve-month accounts receivables. Sequentially, it fell 29.4% from the prior quarter.
Context
- Accounts receivables amounted to 2.2% of revenue in FY2025, down 30.5 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -29.5% toward the trailing-twelve-month pace of -11.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
EUR · from the cash flow
- Latest · FY2025
- 14.97M EUR
- Year-over-year change
- +112.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.97M | +112.6% |
| FY2024 | 2024-12-31 | (118.61M) | -261.9% |
| FY2023 | 2023-12-31 | (32.77M) | -184.2% |
| FY2022 | 2022-12-31 | (11.53M) | -73.2% |
| FY2021 | 2021-12-31 | (6.66M) | — |
Accounts Receivables vs competitors
How ASND compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.3% is the 8th highest of 10, against a peer median of +21.4%.
- Accounts receivables amounts to 7.3% of revenue for ASND, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $60.56B USD | +173755.7% | +40.6% | 5.9% | |
| LTM Sep 2026 | $197.5M USD | -20.0% | +9.1% | 5.3% | |
| LTM Jun 2026 | $162.88M USD | +1189.3% | +139.6% | 14.3% | |
| LTM Sep 2026 | €88.44M EUR | -11.3% | — | 7.3% | |
| LTM Jun 2026 | $69M USD | +177.9% | +48.4% | 2.2% | |
| LTM Mar 2026 | $22.06M USD | -1708.0% | +37.0% | 3.3% | |
| LTM Jun 2026 | $12.35M USD | +15.1% | -30.7% | 1.5% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $10.24M USD | +21.4% | — | 10.6% |
| LTM Mar 2026 | $9.97M USD | +11.8% | -7.4% | 3.2% | |
| LTM Mar 2026 | $4.8M USD | +1478.7% | — | 15.0% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $0 USD | — | — | — |
| Peer median (excluding ASND) | — | +21.4% | +37.0% | 5.3% | |
Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (383.58M) | (583.19M) | (481.45M) | (378.08M) | (219.03M) |
| Depreciation & Amortization | 15.39M | 17.96M | 18.91M | 17.71M | 17M |
| Deferred Income Tax | (367K) | 5.38M | 7.3M | 4.84M | 3.21M |
| Stock-Based Compensation | 66.83M | 64.18M | 66.66M | 95.51M | 0 |
| Change in Working Capital | (47.72M) | (12.47M) | (99.79M) | (107.16M) | 68.16M |
| Accounts Receivables | (6.66M) | (11.53M) | (32.77M) | (118.61M) | 14.97M |
| Inventory | (75.41M) | (55.27M) | (78.26M) | (86.68M) | (5.69M) |
| Accounts Payables | 0 | 0 | 0 | 0 | (9.96M) |
| Other Working Capital | 34.34M | 54.33M | 11.25M | 98.13M | 68.84M |
| Other Non-Cash Items | (68.21M) | 12.45M | 21M | 60.98M | 182.44M |
| Operating Cash Flow | (417.65M) | (495.7M) | (467.36M) | (306.2M) | 51.77M |
| Capital Expenditures | (24.23M) | (14.49M) | (2.44M) | (1.43M) | (8.15M) |
| Acquisitions (Net) | (10.19M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (226.04M) | (213.84M) | 0 | 0 | 0 |
| Sales of Investments | 149.88M | 280.53M | 0 | 7.35M | 0 |
| Other Investing Activities | (530K) | 9.54M | 288.92M | 950K | 0 |
| Investing Cash Flow | (110.58M) | 61.73M | 286.47M | 6.88M | (8.15M) |
| Debt Repayment | (6.43M) | 496.93M | 125.82M | 122.79M | (21.09M) |
| Common Stock Issued | 367.88M | 0 | 0 | 309.91M | 83.64M |
| Common Stock Repurchased | (21.61M) | (105.31M) | (1.81M) | 0 | (16.71M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.54M | 5.15M | 10.29M | 11.22M | (10.95M) |
| Financing Cash Flow | 351.39M | 396.77M | 134.29M | 443.93M | 34.89M |
| Effect of Forex Changes | 38.59M | 35.69M | (6.01M) | 22.77M | 44.13M |
| Net Change in Cash | (138.25M) | (1.5M) | (52.6M) | 167.38M | 122.65M |
| Free Cash Flow | (441.88M) | (510.19M) | (469.8M) | (307.62M) | 43.62M |
Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Alpha fair value
Locked
Current Price
$270.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.